Tags

Type your tag names separated by a space and hit enter

[Transdermal opioid administration: the pain plaster].
Ned Tijdschr Geneeskd. 1997 Apr 26; 141(17):821-3.NT

Abstract

A new method of administration of an opioid was recently registered: fentanyl transdermal (brand name: Durogesic), intended particularly for the indication range 'pain in cancer'. Fentanyl is lipid-soluble so that deposition in the skin takes place and the biological half-life is approximately 20 hours after removal of the plaster. It is safe to start on a basis of an equianalgesic conversion of 100:1 in relation to oral morphine, although this may entail some risk of fentanyl under dosage. The dose adjustment time is 12-24 hours before a constant fentanyl level is reached; therefore, after attaching the first sticking plaster, the original morphine dose should be continued for another 12 hours. In addition, the patient may, if necessary, be given supplementary morphine preferably as a short-acting drug. There seems to be no clear indication for transdermal fentanyl either in neuropathic pain or in chronic benign pain.

Authors+Show Affiliations

Academisch Ziekenhuis Rotterdam-Daniel den Hoed Kliniek, afd. Neuro-oncologie en Pijn-polikliniek, Rotterdam.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

9221362

Citation

Vecht, C J., and P A. Sillevis Smitt. "[Transdermal Opioid Administration: the Pain Plaster]." Nederlands Tijdschrift Voor Geneeskunde, vol. 141, no. 17, 1997, pp. 821-3.
Vecht CJ, Sillevis Smitt PA. [Transdermal opioid administration: the pain plaster]. Ned Tijdschr Geneeskd. 1997;141(17):821-3.
Vecht, C. J., & Sillevis Smitt, P. A. (1997). [Transdermal opioid administration: the pain plaster]. Nederlands Tijdschrift Voor Geneeskunde, 141(17), 821-3.
Vecht CJ, Sillevis Smitt PA. [Transdermal Opioid Administration: the Pain Plaster]. Ned Tijdschr Geneeskd. 1997 Apr 26;141(17):821-3. PubMed PMID: 9221362.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Transdermal opioid administration: the pain plaster]. AU - Vecht,C J, AU - Sillevis Smitt,P A, PY - 1997/4/26/pubmed PY - 1997/4/26/medline PY - 1997/4/26/entrez SP - 821 EP - 3 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 141 IS - 17 N2 - A new method of administration of an opioid was recently registered: fentanyl transdermal (brand name: Durogesic), intended particularly for the indication range 'pain in cancer'. Fentanyl is lipid-soluble so that deposition in the skin takes place and the biological half-life is approximately 20 hours after removal of the plaster. It is safe to start on a basis of an equianalgesic conversion of 100:1 in relation to oral morphine, although this may entail some risk of fentanyl under dosage. The dose adjustment time is 12-24 hours before a constant fentanyl level is reached; therefore, after attaching the first sticking plaster, the original morphine dose should be continued for another 12 hours. In addition, the patient may, if necessary, be given supplementary morphine preferably as a short-acting drug. There seems to be no clear indication for transdermal fentanyl either in neuropathic pain or in chronic benign pain. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/9221362/ DB - PRIME DP - Unbound Medicine ER -